{
    "nct_id": "NCT05953337",
    "official_title": "Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)",
    "inclusion_criteria": "* Must have a confirmed diagnosis of HCC by imaging confirmation with Liver Imaging Reporting and Data System (LIRADS) category 5 or confirmation of HCC via biopsy.\n* No extra hepatic disease.\n* Up to 3 lesions with at least one lesion ≥ 2 cm in diameter (long axis) measurable by computed tomography (CT), CBCT, or MRI. At least one lesion must be identified as a target lesion as defined by mRECIST.\n* Maximal single lesion size of ≤ 8 cm and sum of the maximal tumor dimensions of ≤ 12 cm with the entire tumor burden expected to be treatable within the perfused volume.\n* Intent to treat all lesions within a single session.\n* Hypervascular on CBCT, CT, or MRI.\n* Evidence that > 33% of the total liver volume is disease-free and will be spared Eye90 treatment.\n* Life expectancy of ≥ 6 months.\n* ≥ 18 years old at the time of informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Platelet count <50,000/microliter or prothrombin (PT) activity > 50% normal.\n* Hemoglobin ≤ 8.5 g/dL (subjects that are non-responders to transfusion or medical management must be excluded).\n* INR > 1.7 (if anticoagulated, reversal must be achieved prior to any angiographic procedures).\n* ALT > 5x upper limit.\n* AST > 5x upper limit.\n* Bilirubin ≥ 2.0 mg/dL.\n* eGFR ≤ 50 mL/min/BSA.\n* Macrovascular invasion.\n* Incompetent biliary duct system, prior biliary intervention, or a compromised Ampulla of Vater.\n* Estimated lung dose > 30 Gy as calculated using the lung shunt fraction and partition model.",
    "miscellaneous_criteria": ""
}